Jak neznámý je karcinom neznámého primárního zdroje metastazující do krčních uzlin?

Czech version

Authors: M. Pála
Authors‘ workplace: Ústav radiační onkologie 1. LF UK a FN Bulovka, Praha
Published in: Klin Onkol 2023; 36(5): 364-369
Category: Review
doi: https://doi.org/10.48095/ccko2023364

Overview

Background: The term metastatic carcinoma to cervical lymph nodes from an unknown primary includes a small group of tumors that present themselves with metastases to the cervical nodes, and in which diagnostic methods do not reveal the primary source of these metastases. Histologically, in most cases, these are metastases of squamous cell carcinoma. Carcinomas of unknown primary metastatic to cervical nodes account for < 5% of carcinomas of unknown primary and < 5% of head and neck cancers. The optimal treatment has not yet been defined. In the absence of distant metastases, the intention of treatment is curative. Patients are treated mostly with combined approaches including surgery, radiotherapy, or concomitant chemoradiotherapy. Radiotherapy is part of the treatment algorithm in most of the referenced works and includes irradiation of the mucosal sites of the pharyngeal axis as a potential localization of the primary tumor and unilateral or, more often, bilateral irradiation of the neck. Due to the higher risk of late toxicities observed, individualization of irradiated volumes based on the extent of the disease or other clinical parameters is a rational way to reduce these risks.

Purpose: The presented work discusses the treatment options for patients with metastatic carcinoma to cervical lymph nodes from an unknown primary. Furthermore, the work reports on the high effectiveness of curative radiotherapy in this group of tumors.

Keywords:

Chemoradiotherapy – carcinoma of unknown primary – curative radiotherapy

Sources

1. Comess MS, BeahrsS OH, Dockerty MB. Cervical metastasis from occult carcinoma. Surg Gynecol Obstet 1957; 104 (5): 607–617.

2. Schmalbach CE, Miller FR. Occult primary head and neck carcinoma. Curr Oncol Rep 2007; 9 (2): 139–146. doi: 10.1007/s11912-007-0012-5.

3. Lu X, Hu C, Ji Q et al. Squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: the impact of radiotherapy. Tumori 2009; 95 (2): 185–190. doi: 10.1177/030089160909500209.

4. Wallace A, Richards GM, Harari PM et al. Head and neck squamous cell carcinoma from an unknown primary site. Am J Otolaryngol 2011; 32 (4): 286–290. doi: 10.1016/j.amjoto.2010.05.004.

5. Grau C, Johansen LV, Jakobsen J et al. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55 (2): 121–129. doi: 10.1016/s0167-8140 (00) 00172-9.

6. Sinnathamby K, Peters LJ, Laidlaw C et al. The occult head and neck primary: to treat or not to treat? Clin Oncol 1997; 9 (5): 322–329. doi: 10.1016/s0936-6555 (05) 800 66-4.

7. Erkal HS, Mendenhall WM, Amdur RJ et al. Squamous cell carcinomas metastatic to cervical lymph nodes from an unknown head-and-neck mucosal site treated with radiation therapy alone or in combination with neck dissection. Int J Radiat Oncol Biol Phys 2001; 50 (1): 55–63. doi: 10.1016/s0360-3016 (00) 01554-6.

8. van de Wouw AJ, Jansen RL, Speel EJ et al. The unknown biology of the unknown primary tumour: a literature review. Ann Oncol 2003; 14 (2): 191–196. doi: 10.1093/annonc/mdg068.

9. Cole WH, Everson TC. Spontaneous regression of cancer: preliminary report. Ann Surg 1956; 144 (3): 366–383. doi: 10.1097/00000658-195609000-00007.

10. Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo 1998; 12 (6): 571–578.

11. Paulus P, Sambon A, Vivegnis D et al. 18FDG-PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998; 108 (10): 1578–1583. doi: 10.1097/00005537-199810000-00029.

12. Miller FR, Hussey D, Beeram M et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 2005; 131 (7): 626–629. doi: 10.1001/archotol.131.7.626.

13. Million RR, Cassisi NJ, Mancuso AA. The unknown primary. In: Million RR, Cassisi NJ (eds). Management of head and neck cancer: a multidisciplinary approach. Philadelphia: Lippincott 1994: 311–321.

14. Mendenhall WM, Mancuso AA, Parsons JT et al. Diag‑ nostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20 (8): 739–744. doi: 10.1002/ (sici) 1097-0347 (199812) 20: 8<739:: aid-hed13 >3.0.co; 2-0.

15. Colletier PJ, Garden AS, Morrison WH et al. Postoperative radiation for squamous cell carcinoma metastatic to cervical lymph nodes from an unknown primary site: outcomes and patterns of failure. Head Neck 1998; 20 (8): 674–681. doi: 10.1002/ (sici) 1097-0347 (199812) 20: 8<674:: aid-hed3>3.0.co; 2-h.

16. Tong CC, Luk MY, Chow SM et al. Cervical nodal metastases from occult primary: undifferentiated carcinoma versus squamous cell carcinoma. Head Neck 2002; 24 (4): 361–369. doi: 10.1002/hed.10054.

17. Aslani M, Sultanem K, Voung T et al. Metastatic carcinoma to the cervical nodes from an unknown head and neck primary site: is there a need for neck dissection? Head Neck 2007; 29 (6): 585–590. doi: 10.1002/hed.20581.

18. Cuaron J, Rao S, Wolden S et al. Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy. Head Neck 2016; 38 (Suppl 1): E426–E431. doi: 10.1002/hed.24013.

19. Demiroz C, Vainshtein JM, Koukourakis GV et al. Head and neck squamous cell carcinoma of unknown primary: neck dissection and radiotherapy or definitive radiotherapy. Head Neck 2014; 36 (11): 1589–1595. doi: 10.1002/hed.23479.

20. Dragan AD, Nixon IJ, Guerrero-Urbano MT et al. Selective neck dissection as a therapeutic option in management of squamous cell carcinoma of unknown primary. Eur Arch Otorhinolaryngol 2014; 271 (5): 1249–1256. doi: 10.1007/s00405-013-2643-5.

21. Coster JR, Foote RL, Olsen KD et al. Cervical nodal metastasis of squamous cell carcinoma of unknown origin: indications for withholding radiation therapy. Int J Radiat Oncol Biol Phys 1992; 23 (4): 743–749. doi: 10.1016/0360-3016 (92) 90647-z.

22. Strojan P, Anicin A. Combined surgery and postoperative radiotherapy for cervical lymph node metastases from an unknown primary tumour. Radiother Oncol 1998; 49 (1): 33–40. doi: 10.1016/s0167-8140 (98) 00082-6.

23. Reddy SP, Marks JE. Metastatic carcinoma in the cervical lymph nodes from an unknown primary site: results of bilateral neck plus mucosal irradiation vs. ipsilateral neck irradiation. Int J Radiat Oncol Biol Phys 1997; 37 (4): 797–802. doi: 10.1016/s0360-3016 (97) 00025-4.

24. Nieder C, Gregoire V, Ang KK. Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple? Int J Radiat Oncol Biol Phys 2001; 50 (3): 727–733. doi: 10.1016/s0360-3016 (01) 01462-6.

25. Beldì D, Jereczek-Fossa BA, D‘Onofrio A et al. Role of radiotherapy in the treatment of cervical lymph node metastases from an unknown primary site: retrospective analysis of 113 patients. Int J Radiat Oncol Biol Phys 2007; 69 (4): 1051–1058. doi: 10.1016/j.ijrobp.2007.04.039.

26. Liu X, Li D, Li N et al. Optimization of radiotherapy for neck carcinoma metastasis from unknown primary sites: a meta-analysis. Oncotarget 2016; 7 (48): 78736–78746. doi: 10.18632/oncotarget.12852.

27. Shukla P, Gupta D, Bisht SS et al. Metastatic squamous cell carcinoma neck with occult primary: a retrospective analysis. Indian J Med Paediatr Oncol 2009; 30 (4): 124–130. doi: 10.4103/0971-5851.65334.

28. Tribius S, Hoffmann AS, Bastrop S et al. HPV status in patients with head and neck of carcinoma of unknown primary site: HPV, tobacco smoking, and outcome. Oral Oncol 2012; 48 (11): 1178–1184. doi: 10.1016/j.oraloncology.2012.05.022.

29. Bataini RP, Rodriguez J, Jaulerry C et al. Treatment of metastatic neck nodes secondary to an occult epidermoid carcinoma of the head and neck. Laryngoscope 1987; 97 (9): 1080–1084. doi: 10.1288/00005537-198709000-00015.

30. Harper CS, Mendenhall WM, Parsons JT et al. Cancer in neck nodes with unknown primary site: role of mucosal radiotherapy. Head Neck 1990; 12 (6): 463–469. doi: 10.1002/hed.2880120603.

31. Maulard C, Housset M, Brunel P et al. Postoperative radiation therapy for cervical lymph node metastases from an occult squamous cell carcinoma. Laryngoscope 1992; 102 (8): 884–890. doi: 10.1288/00005537-199208000-00007.

32. Iganej S, Kagan R, Anderson P et al. Metastatic squamous cell carcinoma of the neck from an unknown primary: management options and patterns of relapse. Head Neck 2002; 24 (3): 236–246. doi: 10.1002/hed.10017.

33. Rödel RM, Matthias C, Blomeyer BD et al. Impact of distant metastasis in patients with cervical lymph node metastases from cancer of an unknown primary site. Ann Otol Rhinol Laryngol 2009; 118 (9): 662–669. doi: 10.1177/000348940911800911.

34. Ligey A, Gentil J, Créhange G et al. Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary. Radiother Oncol 2009; 93 (3): 483–487. doi: 10.1016/j.radonc.2009.08.027.

35. Fakhrian K, Thamm R, Knapp S et al. Radio (chemo) therapy in the management of squamous cell carcinoma of cervical lymph nodes from an unknown primary site. A retrospective analysis. Strahlenther Onkol 2012; 188 (1): 56–61. doi: 10.1007/s00066-011-0017-8.

36. Al Kadah B, Papaspyrou G, Linxweiler M et al. Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients. Eur Arch Otorhinolaryngol 2017; 274 (6): 2557–2566. doi: 10.1007/s00405-017-4525-8.

37. Frank SJ, Rosenthal DI, Petsuksiri J et al. Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2010; 78 (4): 1005–1010. doi: 10.1016/j.ijrobp.2009.09.006.

38. Klem ML, Mechalakos JG, Wolden SL et al. Intensity-modulated radiotherapy for head and neck cancer of unknown primary: toxicity and preliminary efficacy. Int J Radiat Oncol Biol Phys 2008; 70 (4): 1100–1107. doi: 10.1016/j.ijrobp.2007.07.2351.

39. Madani I, Vakaet L, Bonte K et al. Intensity-modulated radiotherapy for cervical lymph node metastases from unknown primary cancer. Int J Radiat Oncol Biol Phys 2008; 71 (4): 1158–1166. doi: 10.1016/j.ijrobp.2007.11.059.

40. Lu H, Yao M, Tan H. Unknown primary head and neck cancer treated with intensity-modulated radiation therapy: to what extent the volume should be irradiated. Oral Oncol 2009; 45 (6): 474–479. doi: 10.1016/j.oraloncology.2008.06.006.

41. Sher DJ, Balboni TA, Haddad RI et al. Efficacy and toxicity of chemoradiotherapy using intensity-modulated radiotherapy for unknown primary of head and neck. Int J Radiat Oncol Biol Phys 2011; 80 (5): 1405–1411. doi: 10.1016/j.ijrobp.2010.04.029.

42. Shoushtari A, Saylor D, Kerr KL et al. Outcomes of patients with head-and-neck cancer of unknown primary origin treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81 (3): e83–e91. doi: 10.1016/j.ijrobp.2011.01.014.

43. Chen AM, Farwell DG, Lau DH et al. Radiation therapy in the management of head-and-neck cancer of unknown primary origin: how does the addition of concurrent chemotherapy affect the therapeutic ratio? Int J Radiat Oncol Biol Phys 2011; 81 (2): 346–352. doi: 10.1016/j.ijrobp.2010.06.031.

44. Villeneuve H, Després P, Fortin B et al. Cervical lymph node metastases from unknown primary cancer: a single-institution experience with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2012; 82 (5): 1866–1871. doi: 10.1016/j.ijrobp.2011.02.031.

45. Maghami E, Ismaila N, Alvarez A et al. Diagnosis and management of squamous cell carcinoma of unknown primary in the head and neck: ASCO guideline. J Clin Oncol 2020; 38 (22): 2570–2596. doi: 10.1200/JCO.20.00275.

46. Pala M, Novakova P, Pechacova Z et al. Long-term results of radio (chemo) therapy in metastatic carcinoma to cervical lymph nodes from an unknown primary. Adult Comorbidity Evaluation 27 score as a predictor of survival. Strahlenther Onkol 2023; 199 (2): 149–159. doi: 10.1007/s00066-022-01983-6.